These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36178085)

  • 1. Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortality.
    Pidsley R; Lam D; Qu W; Peters TJ; Luu PL; Korbie D; Stirzaker C; Daly RJ; Stricker P; Kench JG; Horvath LG; Clark SJ
    Clin Transl Med; 2022 Oct; 12(10):e1030. PubMed ID: 36178085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer.
    Zhao S; Geybels MS; Leonardson A; Rubicz R; Kolb S; Yan Q; Klotzle B; Bibikova M; Hurtado-Coll A; Troyer D; Lance R; Lin DW; Wright JL; Ostrander EA; Fan JB; Feng Z; Stanford JL
    Clin Cancer Res; 2017 Jan; 23(1):311-319. PubMed ID: 27358489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in the methylome of the stromal tumour microenvironment signal the presence and severity of prostate cancer.
    Lawrence MG; Pidsley R; Niranjan B; Papargiris M; Pereira BA; Richards M; Teng L; Norden S; Ryan A; Frydenberg M; Stirzaker C; Taylor RA; Risbridger GP; Clark SJ
    Clin Epigenetics; 2020 Mar; 12(1):48. PubMed ID: 32188493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
    Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
    Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
    Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
    Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
    Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
    PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
    Strand SH; Switnicki M; Moller M; Haldrup C; Storebjerg TM; Hedegaard J; Nordentoft I; Hoyer S; Borre M; Pedersen JS; Wild PJ; Park JY; Orntoft TF; Sorensen KD
    Oncotarget; 2017 Jan; 8(4):5774-5788. PubMed ID: 28052017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate tumor DNA methylation is associated with cigarette smoking and adverse prostate cancer outcomes.
    Shui IM; Wong CJ; Zhao S; Kolb S; Ebot EM; Geybels MS; Rubicz R; Wright JL; Lin DW; Klotzle B; Bibikova M; Fan JB; Ostrander EA; Feng Z; Stanford JL
    Cancer; 2016 Jul; 122(14):2168-77. PubMed ID: 27142338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive evaluation of targeted multiplex bisulphite PCR sequencing for validation of DNA methylation biomarker panels.
    Lam D; Luu PL; Song JZ; Qu W; Risbridger GP; Lawrence MG; Lu J; Trau M; Korbie D; Clark SJ; Pidsley R; Stirzaker C
    Clin Epigenetics; 2020 Jun; 12(1):90. PubMed ID: 32571390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer.
    Kim JH; Dhanasekaran SM; Prensner JR; Cao X; Robinson D; Kalyana-Sundaram S; Huang C; Shankar S; Jing X; Iyer M; Hu M; Sam L; Grasso C; Maher CA; Palanisamy N; Mehra R; Kominsky HD; Siddiqui J; Yu J; Qin ZS; Chinnaiyan AM
    Genome Res; 2011 Jul; 21(7):1028-41. PubMed ID: 21724842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer.
    Wu Y; Davison J; Qu X; Morrissey C; Storer B; Brown L; Vessella R; Nelson P; Fang M
    Epigenetics; 2016 Apr; 11(4):247-58. PubMed ID: 26890304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenome-Wide Association Study of Prostate Cancer in African Americans Identifies DNA Methylation Biomarkers for Aggressive Disease.
    Xu Y; Tsai CW; Chang WS; Han Y; Huang M; Pettaway CA; Bau DT; Gu J
    Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.
    Cho NY; Kim BH; Choi M; Yoo EJ; Moon KC; Cho YM; Kim D; Kang GH
    J Pathol; 2007 Feb; 211(3):269-77. PubMed ID: 17139617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-pass whole genome bisulfite sequencing of neonatal dried blood spots identifies a role for RUNX1 in Down syndrome DNA methylation profiles.
    Laufer BI; Hwang H; Jianu JM; Mordaunt CE; Korf IF; Hertz-Picciotto I; LaSalle JM
    Hum Mol Genet; 2021 Jan; 29(21):3465-3476. PubMed ID: 33001180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenomic alterations in localized and advanced prostate cancer.
    Lin PC; Giannopoulou EG; Park K; Mosquera JM; Sboner A; Tewari AK; Garraway LA; Beltran H; Rubin MA; Elemento O
    Neoplasia; 2013 Apr; 15(4):373-83. PubMed ID: 23555183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
    Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
    Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Random forest-based modelling to detect biomarkers for prostate cancer progression.
    Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
    Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cord blood DNA methylome in newborns later diagnosed with autism spectrum disorder reflects early dysregulation of neurodevelopmental and X-linked genes.
    Mordaunt CE; Jianu JM; Laufer BI; Zhu Y; Hwang H; Dunaway KW; Bakulski KM; Feinberg JI; Volk HE; Lyall K; Croen LA; Newschaffer CJ; Ozonoff S; Hertz-Picciotto I; Fallin MD; Schmidt RJ; LaSalle JM
    Genome Med; 2020 Oct; 12(1):88. PubMed ID: 33054850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lowly methylated region analysis identifies EBF1 as a potential epigenetic modifier in breast cancer.
    Fernandez-Jimenez N; Sklias A; Ecsedi S; Cahais V; Degli-Esposti D; Jay A; Ancey PB; Woo HD; Hernandez-Vargas H; Herceg Z
    Epigenetics; 2017; 12(11):964-972. PubMed ID: 29099283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue.
    Geybels MS; Zhao S; Wong CJ; Bibikova M; Klotzle B; Wu M; Ostrander EA; Fan JB; Feng Z; Stanford JL
    Prostate; 2015 Dec; 75(16):1941-50. PubMed ID: 26383847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.